沙库巴曲缬沙坦对慢性缺血性心肌病导致心力衰竭的临床疗效观察

Clinical effect of sacubitril/valsartan on chronic heart failure due to ischemic cardiomyopathy

目的探讨沙库巴曲缬沙坦对缺血性心肌病患者慢性心力衰竭的临床疗效。方法选择2018年9月至2019年9月宁波市鄞州区第二医院缺血性心肌病合并慢性心力衰竭的患者48例,依据就诊日期单双日分为观察组25例和对照组23例,分别服用沙库巴曲缬沙坦和氯沙坦。治疗6个月,观察并比较两组患者心功能、脑钠肽前体(NT-proBNP)、左心室射血分数(LVEF)和左心室舒张末内径(LVEDd)的变化及不良反应情况。结果6个月后观察组总有效率高于对照组,差异有统计学意义(P<0.05)。观察组NT-proBNP、LVEDd低于对照组,LVEF高于对照组,差异均有统计学意义(均P<0.05)。两组患者不良反应发生率比较,差异均无统计学意义(均P>0.05)。结论沙库巴曲缬沙坦用于缺血性心肌病导致慢性心力衰竭疗效显著。

Objective To explore the effects of sacubitril/valsartan on chronic heart failure(CHF)in patients with ischemic cardiomyopathy.Methods 48 patients with CHF and ischemic cardiomyopathy were enrolled in Ningbo Yinzhou No.2 Hospital from September 2018 to September 2019.They were randomly divided into observation group(n=25)and control group(n=23)based on the odd or even number of admission date,and treated with sacubitril/valsartan and losartan,respectively,for 6 months.The changes of heart function,NT-pro BNP,left ventricular ejection(LVEF)and left ventricular end-diastolic dimension(LVEDd)and adverse reactions were observed and compared between the two groups.Results The total effective rate in the observation group was significantly higher than that in the control group after 6 months of treatment(P<0.05).NT-proBNP and LVEDd were significantly lower and LVEF was significantly higher in the observation group than in the control group(all P<0.05).The incidence of adverse reactions was not significantly different between the two groups.Conclusion Sacubitril/valsartan is effective in treatment of CHF resulting fromischemic cardiomyopathy.